Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 0.86 |
| ▸ | HDAC3 | O15379 | 18/20 | 0.86 |
| ▸ | HDAC2 | Q92769 | 16/20 | 0.86 |
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.86 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.86 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.86 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.82 |
| ▸ | NCOR2 | Q9Y618 | 8/20 | 0.82 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.82 |
| ▸ | UBA1 | P22314 | 1/20 | 0.82 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8035633 | 1.00 | HDAC1 (0.86) | HDAC1HDAC3HDAC2HDAC6HDAC10 | |
| SCHEMBL15827286 | 1.00 | HDAC1 (0.86) | HDAC1HDAC3HDAC2HDAC6HDAC10 | |
| SCHEMBL71678 | 1.00 | HDAC1 (0.86) | HDAC1HDAC3HDAC2HDAC6HDAC10 | |
| SCHEMBL71351 | 0.92 | HDAC3 (0.90) | HDAC1HDAC3HDAC2HDAC6HDAC10 | |
| SCHEMBL16203381 | 0.92 | HDAC3 (0.90) | HDAC1HDAC3HDAC2HDAC6HDAC10 | |
| Largazole SCHEMBL23760411 | 0.90 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC10 | |
| Largazole SCHEMBL71330 | 0.90 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC10 | |
| Largazole SCHEMBL2611945 | 0.90 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC10 | |
| Largazole SCHEMBL91139 | 0.90 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC10 | |
| Largazole SCHEMBL23760414 | 0.90 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110123644-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123644-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC3 3/4885HDAC2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.